Critical Limb Ischemia: Cell and Molecular Therapies for Limb Salvage

Overview

Journal Methodist Debakey Cardiovasc J

Specialty Cardiology & Vascular Diseases

Date 2013 Jan 24

PMID 23342184

Citations 12

Authors

Mark G Davies

Affiliations

Soon will be listed here.

Abstract

There is a growing interest in developing new limb salvage therapies for patients with severe peripheral artery disease who have no alternative to amputation. Cell and gene therapy studies are showing promise in controlling pain and minor ulceration in patients with significant critical limb ischemia. Among cardiovascular cell and molecular therapy programs, The Methodist Hospital is one of the leading centers in both gene and cell therapy for critical limb ischemia. Randomized controlled trials continue to be performed, and these experimental therapies will move from research to pharmacy within the decade. In conjunction with aggressive medical and surgical management, these emergent therapies may help patients with critical limb ischemia avoid a major amputation and are one of the foundations of any advanced limb salvage program.

Citing Articles

Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome.

Barc P, Antkiewicz M, Fraczkowska-Sioma K, Kupczynska D, Lubieniecki P, Witkiewicz W Int J Environ Res Public Health. 2022; 19(19).

PMID: 36232122 PMC: 9564889. DOI: 10.3390/ijerph191912818.

Role of Lipid-Lowering Therapy in Peripheral Artery Disease.

Belur A, Shah A, Virani S, Vorla M, Kalra D J Clin Med. 2022; 11(16).

PMID: 36013107 PMC: 9410277. DOI: 10.3390/jcm11164872.

Assessment of endothelial colony forming cells delivery routes in a murine model of critical limb threatening ischemia using an optimized cell tracking approach.

Rojas-Torres M, Sanchez-Gomar I, Rosal-Vela A, Beltran-Camacho L, Eslava-Alcon S, Alonso-Pineiro J Stem Cell Res Ther. 2022; 13(1):266.

PMID: 35729651 PMC: 9210810. DOI: 10.1186/s13287-022-02943-8.

Collateral Arteriogenesis Involves a Sympathetic Denervation That Is Associated With Abnormal α-Adrenergic Signaling and a Transient Loss of Vascular Tone.

Silva A, Hatch C, Chu M, Cardinal T Front Cardiovasc Med. 2022; 9:805810.

PMID: 35242824 PMC: 8886147. DOI: 10.3389/fcvm.2022.805810.

Efficient generation of endothelial cells from induced pluripotent stem cells derived from a patient with peripheral arterial disease.

Boonkaew B, Suwanpitak S, Pattanapanyasat K, Sermsathanasawadi N, Wattanapanitch M Cell Tissue Res. 2022; 388(1):89-104.

PMID: 35072793 DOI: 10.1007/s00441-022-03576-2.

References

Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi M . Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia. Mol Ther. 2017; 16(5):972-978. DOI: 10.1038/mt.2008.33. View

Gu Y, Zhang J, Guo L, Cui S, Li X, Ding D . A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med. 2011; 13(11):602-10. DOI: 10.1002/jgm.1614. View

Hirsch A, Haskal Z, Hertzer N, Bakal C, Creager M, Halperin J . ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for.... Circulation. 2006; 113(11):e463-654. DOI: 10.1161/CIRCULATIONAHA.106.174526. View

Walter D, Krankenberg H, Balzer J, Kalka C, Baumgartner I, Schluter M . Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011; 4(1):26-37. DOI: 10.1161/CIRCINTERVENTIONS.110.958348. View

Hirschi K, Goodell M . Common origins of blood and blood vessels in adults?. Differentiation. 2002; 68(4-5):186-92. DOI: 10.1046/j.1432-0436.2001.680406.x. View

Zhu S, Liu X, Li Y, Goldschmidt-Clermont P, Dong C . Aging in the atherosclerosis milieu may accelerate the consumption of bone marrow endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2006; 27(1):113-9. DOI: 10.1161/01.ATV.0000252035.12881.d0. View

Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85(3):221-8. DOI: 10.1161/01.res.85.3.221. View

Amann B, Luedemann C, Ratei R, Schmidt-Lucke J . Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009; 18(3):371-80. DOI: 10.3727/096368909788534942. View

Risau W . Mechanisms of angiogenesis. Nature. 1997; 386(6626):671-4. DOI: 10.1038/386671a0. View

10.

Powell R, Marston W, Berceli S, Guzman R, Henry T, Longcore A . Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012; 20(6):1280-6. PMC: 3369291. DOI: 10.1038/mt.2012.52. View

11.

Hirota K, Semenza G . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59(1):15-26. DOI: 10.1016/j.critrevonc.2005.12.003. View

12.

Lederman R, Mendelsohn F, Anderson R, Saucedo J, Tenaglia A, Hermiller J . Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002; 359(9323):2053-8. DOI: 10.1016/s0140-6736(02)08937-7. View

13.

Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998; 97(12):1114-23. DOI: 10.1161/01.cir.97.12.1114. View

14.

Bartsch T, Brehm M, Zeus T, Kogler G, Wernet P, Strauer B . Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol. 2007; 96(12):891-9. DOI: 10.1007/s00392-007-0569-x. View

15.

Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M . Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008; 156(5):1010-8. DOI: 10.1016/j.ahj.2008.06.025. View

16.

de Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C . Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels. 2009; 24(5):321-8. DOI: 10.1007/s00380-008-1140-z. View

17.

Franz R, Parks A, Shah K, Hankins T, Hartman J, Wright M . Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. J Vasc Surg. 2009; 50(6):1378-90. DOI: 10.1016/j.jvs.2009.07.113. View

18.

van Tongeren R, Hamming J, Fibbe W, van Weel V, Frerichs S, Stiggelbout A . Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino). 2008; 49(1):51-8. View

19.

Powell R, Simons M, Mendelsohn F, Daniel G, Henry T, Koga M . Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008; 118(1):58-65. DOI: 10.1161/CIRCULATIONAHA.107.727347. View

20.

Adam D, Beard J, Cleveland T, Bell J, Bradbury A, Forbes J . Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005; 366(9501):1925-34. DOI: 10.1016/S0140-6736(05)67704-5. View